RP1, Nivolumab
Replimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock Surges
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the treatment of advanced melanoma. Following the announcement, Replimune's stock is currently climbing 26.09 percent, to $12.78 on the Nasdaq.
Australian researchers have made a breakthrough in improving the cure rate for the most common form of breast cancer. An ...
The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...
Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...
Hosted on MSN23h
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLAReplimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...
In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab ...
Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Adults with stage IB-IIIA (American Joint Committee on Cancer seventh edition) resectable NSCLC ...
During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback